免疫介导性肾脏病发病机制与治疗进展综述
本综述从直接和间接免疫介导机制角度,总结了免疫介导性肾脏病在抗原发现与治疗试验方面的最新进展。直接机制涉及抗GBM病和膜性肾病的新抗原及膜性肾病、FSGS的新方案;间接机制涉及ANCA血管炎、狼疮肾炎和IgA肾病的关键试验。还描述了旁路补体途径的新分子通路及相关实验性治疗。
要点
- 抗GBM病和膜性肾病有新抗原被发现,膜性肾病和FSGS有新治疗方案。
- ANCA血管炎、狼疮肾炎和IgA肾病的关键试验从真实实践角度被审视。
- 旁路补体途径新分子通路催生了多种实验性治疗。
核心结论
- 免疫介导性肾脏病发病机制认识快速进步,已推动多种治疗药物开发并持续改善肾脏与患者结局。
研究设计与样本
- 综述类文章,检索范围未在摘要中明确报告。
主要发现
- 直接免疫介导病中,抗GBM病和膜性肾病有新描述的抗原,膜性肾病和FSGS有新治疗方案。
- 间接免疫介导病中,ANCA血管炎、狼疮肾炎和IgA肾病有近期关键试验从真实实践角度被审视。
- 旁路补体途径疾病的新分子通路被描述,并促成多种实验性治疗开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There continues to be rapid advancement in our understanding of the pathogenesis of immune-mediated kidney disease. This progress has culminated in the development of multiple therapeutic agents that have consistently improved renal and patient outcomes. The focus of this review is to discuss these recent advancements in immune-mediated kidney disease via the lens of direct and indirect immune-mediated mechanisms. In the direct immune-mediated disease, recently described antigens in anti-glomerular basement membrane (GBM) disease and membranous nephropathy are discussed, along with new therapeutic regimens in membranous nephropathy and focal segmental glomerulosclerosis. From an indirect immune-mediated disease standpoint, recent pivotal trials in antineutrophil cytoplasmic antibody vasculitis, lupus nephritis, and IgA nephropathy are examined from a real-world practice perspective. New molecular pathways in various disorders of alternate complement pathway are described, which in turn have led to development of various experimental therapies. In addition, pivotal and ongoing therapeutic trials in the aforementioned diseases are presented.
引用
- Kant S, Kronbichler A, Sharma P, et al. Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review. Am J Kidney Dis. 2021. PMID: 34508831. doi:10.1053/j.ajkd.2021.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。